Home » Stocks » THTX

Theratechnologies Inc. (THTX)

Stock Price: $3.50 USD -0.08 (-2.23%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 332.31M
Revenue (ttm) 55.32M
Net Income (ttm) -20.53M
Shares Out 94.95M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE 55.87
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.50
Previous Close $3.58
Change ($) -0.08
Change (%) -2.23%
Day's Open 3.68
Day's Range 3.47 - 3.68
Day's Volume 109,663
52-Week Range 1.83 - 4.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Theratechnologies Inc (NASDAQ: THTX) has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for its Phase 3 trial for tesamorelin in nonalc...

1 week ago - Benzinga

MONTREAL, July 15, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization...

1 week ago - GlobeNewsWire

MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- In a release issued this morning, Wednesday, June 30, 2021, under the same headline, by Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), please note that in t...

3 weeks ago - GlobeNewsWire

MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovativ...

3 weeks ago - GlobeNewsWire

MONTREAL, June 23, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

1 month ago - GlobeNewsWire

Theratechnologies Inc (NASDAQ: THTX) has announced new preclinical in vivo findings on its peptide-drug conjugate (PDC), TH1902. The results demonstrate that TH1902 has better anti-metastatic activity w...

1 month ago - Benzinga

Demonstrates better anti-metastatic activity compared with docetaxel alone

1 month ago - GlobeNewsWire

MONTREAL, May 31, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (TSX: TH) (NASDAQ: THTX)), a biopharmaceutical company focused on the development and commercializati...

1 month ago - GlobeNewsWire

100% of patients expressed satisfaction with treatment experience

2 months ago - GlobeNewsWire

MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative...

2 months ago - GlobeNewsWire

MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization o...

2 months ago - GlobeNewsWire

MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization...

3 months ago - GlobeNewsWire

MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

3 months ago - GlobeNewsWire

MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovati...

3 months ago - GlobeNewsWire

TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone

3 months ago - GlobeNewsWire

MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the dev...

3 months ago - GlobeNewsWire

MONTREAL, March 24, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

4 months ago - GlobeNewsWire

Theratechnologies (THTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company

4 months ago - Zacks Investment Research

Data presented at ENDO 2021 Data presented at ENDO 2021

4 months ago - GlobeNewsWire

MONTREAL, March 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

4 months ago - GlobeNewsWire

MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

4 months ago - GlobeNewsWire

Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively

4 months ago - GlobeNewsWire

MONTREAL, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovativ...

5 months ago - GlobeNewsWire

The FDA has designated Fast Track status to Theratechnologies Inc's (NASDAQ: THTX) TH1902 as a single agent for treating patients with sortilin positive recurrent advanced solid tumors that are refracto...

5 months ago - Benzinga

MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

5 months ago - GlobeNewsWire

MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerciali...

6 months ago - GlobeNewsWire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

6 months ago - GlobeNewsWire

MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

6 months ago - GlobeNewsWire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

6 months ago - GlobeNewsWire

I n addition to ovarian and triple-negative breast cancers , TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers

7 months ago - GlobeNewsWire

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

8 months ago - GlobeNewsWire

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

8 months ago - GlobeNewsWire

MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

8 months ago - GlobeNewsWire

MONTREAL, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

8 months ago - GlobeNewsWire

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

9 months ago - GlobeNewsWire

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

9 months ago - GlobeNewsWire

MONTREAL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

9 months ago - GlobeNewsWire

MONTREAL, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended Augus...

9 months ago - GlobeNewsWire

MONTREAL, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

9 months ago - GlobeNewsWire

MONTREAL, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innova...

10 months ago - GlobeNewsWire

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021

10 months ago - GlobeNewsWire

First commercial launch in Europe

10 months ago - GlobeNewsWire

MONTREAL, July 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the ...

11 months ago - GlobeNewsWire

Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma

11 months ago - Seeking Alpha

Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat

1 year ago - GlobeNewsWire

MONTREAL, July 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of sharehol...

1 year ago - GlobeNewsWire

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020-

1 year ago - GlobeNewsWire

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystr... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1993
CEO
Paul Levesque
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
THTX
Full Company Profile

Financial Performance

In 2020, THTX's revenue was 66.05 million, an increase of 4.49% compared to the previous year's 63.22 million. Losses were -22.67 million, 81.4% more than in 2019.

Financial numbers in millions CAD.
Financial Statements